Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stevo Julius

Showing results (91-100 of 118) with videos related to

Pageof 12
Sort By:
Lancet (London, England)|June 23, 2004
Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE TrialMichael A Weber, Stevo Julius, Sverre E Kjeldsen, et al.
Journal of Hypertension|March 17, 2016
Management of the hypertensive patient with elevated heart rate: Statement of the Second Consensus Conference endorsed by the European Society of HypertensionPaolo Palatini, Enrico Agabiti Rosei, Edoardo Casiglia, et al.
American Journal of Hypertension|January 26, 2008
Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE studyPeter M Okin, Kristian Wachtell, Richard B Devereux, et al.
Lancet (London, England)|April 9, 2002
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololBjörn Dahlöf, Richard B Devereux, Sverre E Kjeldsen, et al.
The American Journal of Cardiology|December 16, 2011
Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertensionStevo Julius, Paolo Palatini, Sverre E Kjeldsen, et al.
Journal of the American College of Cardiology|March 1, 2005
Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) studyKristian Wachtell, Björn Hornestam, Mika Lehto, et al.
Blood Pressure|July 9, 2008
Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trialSverre E Kjeldsen, Gordon T McInnes, Giuseppe Mancia, et al.
Kidney International|February 12, 2004
The impact of serum uric acid on cardiovascular outcomes in the LIFE studyAud Høieggen, Michael H Alderman, Sverre E Kjeldsen, et al.
American Journal of Hypertension|August 6, 2002
Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: the LIFE study. Losartan Intervention For EndpointPeter M Okin, Jackson T Wright, Markku S Nieminen, et al.
Hypertension (Dallas, Tex. : 1979)|January 19, 2005
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension studyHans Ibsen, Michael H Olsen, Kristian Wachtell, et al.
Pageof 12

Showing results (91-100 of 118) with videos related to

Sort By:
Pageof 12
Lancet (London, England)|June 23, 2004
Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE TrialMichael A Weber, Stevo Julius, Sverre E Kjeldsen, et al.
Journal of Hypertension|March 17, 2016
Management of the hypertensive patient with elevated heart rate: Statement of the Second Consensus Conference endorsed by the European Society of HypertensionPaolo Palatini, Enrico Agabiti Rosei, Edoardo Casiglia, et al.
American Journal of Hypertension|January 26, 2008
Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE studyPeter M Okin, Kristian Wachtell, Richard B Devereux, et al.
Lancet (London, England)|April 9, 2002
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololBjörn Dahlöf, Richard B Devereux, Sverre E Kjeldsen, et al.
The American Journal of Cardiology|December 16, 2011
Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertensionStevo Julius, Paolo Palatini, Sverre E Kjeldsen, et al.
Journal of the American College of Cardiology|March 1, 2005
Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) studyKristian Wachtell, Björn Hornestam, Mika Lehto, et al.
Blood Pressure|July 9, 2008
Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trialSverre E Kjeldsen, Gordon T McInnes, Giuseppe Mancia, et al.
Kidney International|February 12, 2004
The impact of serum uric acid on cardiovascular outcomes in the LIFE studyAud Høieggen, Michael H Alderman, Sverre E Kjeldsen, et al.
American Journal of Hypertension|August 6, 2002
Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: the LIFE study. Losartan Intervention For EndpointPeter M Okin, Jackson T Wright, Markku S Nieminen, et al.
Hypertension (Dallas, Tex. : 1979)|January 19, 2005
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension studyHans Ibsen, Michael H Olsen, Kristian Wachtell, et al.
Pageof 12